Seminars in Ophthalmology最新文献

Lens-Induced Uveitis: A Systematic Review of Pathophysiology, Diagnosis, and Treatment. 晶状体引起的葡萄膜炎：病理生理、诊断和治疗的系统综述。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-08 DOI: 10.1080/08820538.2026.2670454

María Elisa Rodríguez-Malagón, Andrea Salazar-Vitale, Natalia Mayela Cantón-Muñiz, Rogelio Jaime Correa-Chapa, Alejandro Rodriguez-Garcia

{"title":"Lens-Induced Uveitis: A Systematic Review of Pathophysiology, Diagnosis, and Treatment.","authors":"María Elisa Rodríguez-Malagón, Andrea Salazar-Vitale, Natalia Mayela Cantón-Muñiz, Rogelio Jaime Correa-Chapa, Alejandro Rodriguez-Garcia","doi":"10.1080/08820538.2026.2670454","DOIUrl":"https://doi.org/10.1080/08820538.2026.2670454","url":null,"abstract":"Introduction: Lens-induced uveitis is an adaptive, immune-mediated reaction to lens proteins that are exposed to the anterior chamber. Although uncommon, its clinical presentation and management remain variable, and no standardized care algorithm exists. We aim to review the clinical characteristics, diagnostic approaches, and therapeutic strategies for lens-induced uveitis as reported in the literature.Methods: A systematic review was conducted using PubMed, Web of Science, CINAHL, Google Scholar, Cochrane, and Scopus databases up to October 31, 2025.Results: Twenty-nine studies encompassing 252 eyes were included. Most cases (82.54%) involved a disrupted lens capsule, consistent with the central role of crystallin exposure in triggering a phacogenic inflammatory response. At final follow-up, 64.69% of eyes had a visual acuity of light perception or worse. Surgical removal of lens material was the predominant definitive treatment, and earlier intervention in more recent reports appeared associated with better visual outcomes.Discussion: Lens-induced uveitis remains a vision-threatening condition largely driven by delayed diagnosis and persistent exposure to lens-derived antigens. Early clinical recognition and timely surgical removal of antigenic material are essential to avoid irreversible inflammatory damage. Improved awareness of its characteristic clinical features may support earlier intervention and better visual outcomes.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

5-Year Surgical Success and Outcomes of XEN-45 Microstent Combined with Cataract Surgery. XEN-45微支架联合白内障手术的5年手术成功率和疗效。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-06 DOI: 10.1080/08820538.2026.2667852

Büşra Yılmaz Tuğan, Büşra Kurt Musaoğlu, Nurşen Yüksel

{"title":"5-Year Surgical Success and Outcomes of XEN-45 Microstent Combined with Cataract Surgery.","authors":"Büşra Yılmaz Tuğan, Büşra Kurt Musaoğlu, Nurşen Yüksel","doi":"10.1080/08820538.2026.2667852","DOIUrl":"https://doi.org/10.1080/08820538.2026.2667852","url":null,"abstract":"Purpose: To evaluate long-term intraocular pressure (IOP), number of antiglaucoma medications (AGMs), and success after phacoemulsification combined with XEN-45 implantation (Phaco+XEN-45), and to compare these outcomes between primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PEXG).Methods: This retrospective study included 30 patients (30 eyes; 17 POAG, 13 PEXG) who underwent Phaco+XEN-45 implantation. IOP, number of AGMs, postoperative interventions, complete or qualified surgical success (IOP of 5-18 mmHg with AGMs or independent of AGMs, respectively), and failure (failure to achieve qualified success) were evaluated at 1, 2, 3, 4, 5 years postoperatively and at the final follow-up.Results: The median IOP at baseline was 20.5 (14.8-26.5) mmHg and decreased to 16.0 (14.8-17.3) mmHg at 5 years. The median number of AGMs decreased from 3.0 (2.0-3.3) at baseline to 2.0 (0.0-2.3) at 5-year, presenting a significant reduction at all follow-up time points (p < .001). The median IOP did not differ between POAG and PEXG during follow-up, whereas PEXG required more AGMs at 1 and 2 years (p = .048 and p = .031, respectively). Kaplan-Meier analysis showed complete success rates of 60% and 36% and qualified success rates of 100% and 96%, at 1 and 5 years, respectively; with 70% qualified success rate at 8 years. Long-term success did not differ between the POAG and PEXG groups.Conclusion: Phaco+XEN-45 implantation offers a significant reduction in AGMs and a marked decrease in IOP, with an acceptable long-term efficacy and safety profile. The similarity in the success rates of POAG and PEXG suggests that Phaco+XEN-45 is a feasible and safe option for both types of glaucoma with appropriate patient selection and effective postoperative bleb modulation.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147842385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features, Diagnosis and Prognosis of Vemurafenib-Induced Uveitis. vemurafenib致葡萄膜炎的临床特点、诊断及预后。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-05 DOI: 10.1080/08820538.2026.2670451

Zhaoquan Wu, Wei Sun, Chunjiang Wang

{"title":"Clinical Features, Diagnosis and Prognosis of Vemurafenib-Induced Uveitis.","authors":"Zhaoquan Wu, Wei Sun, Chunjiang Wang","doi":"10.1080/08820538.2026.2670451","DOIUrl":"https://doi.org/10.1080/08820538.2026.2670451","url":null,"abstract":"Purpose: To investigate the clinical features of vemurafenib-induced uveitis and to provide clinical evidence for diagnosis and treatment.Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and collected clinical reports on vemurafenib-induced uveitis by searching Chinese and English databases up to January 31, 2026. Clinical data were extracted and descriptive analysis was conducted.Results: A total of 33 patients were collected, with a median age of 58 years (range 14,81). The median occurrence time of uveitis was 6 months (range 0.75, 48), with ocular redness (37.39%) and blurry vision (34.5%) as the main symptoms. Uveitis mainly involved bilateral eyes (87.9%), mainly anterior uveitis (60.6%). Optical coherence tomography examination can show normal (25.9%) and macular edema (51.9%). After discontinuing vemurafenib and receiving local, topical and/or systemic steroids, the patient's symptoms gradually improved.Conclusion: Patients taking vemurafenib are recommended to undergo ophthalmic monitoring. During treatment, clinicians should be alert to the potential for uveitis, particularly if patients develop ocular redness and visual impairment. While the optimal treatment regimen for vemurafenib-induced uveitis is not established, topical, local, and/or systemic steroids continue to be the primary treatment approach.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147842415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential Sex-Based Enrolment into US-Registered Glaucoma Clinical Trials: A Cross-Sectional Study. 在美国注册的青光眼临床试验中基于性别的差异入组：一项横断面研究。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2025-08-28 DOI: 10.1080/08820538.2025.2553697

Brendan K Tao, Jim S Xie, Anastasiya Vinokurtseva, John Liu, Hareshan Suntharalingam, Manvis Xia, Nawaaz Nathoo, Matthew Schlenker, Kulbir Gill, Cindy M L Hutnik

{"title":"Differential Sex-Based Enrolment into US-Registered Glaucoma Clinical Trials: A Cross-Sectional Study.","authors":"Brendan K Tao, Jim S Xie, Anastasiya Vinokurtseva, John Liu, Hareshan Suntharalingam, Manvis Xia, Nawaaz Nathoo, Matthew Schlenker, Kulbir Gill, Cindy M L Hutnik","doi":"10.1080/08820538.2025.2553697","DOIUrl":"10.1080/08820538.2025.2553697","url":null,"abstract":"Purpose: We conducted a cross-sectional study of sex, racial, and ethnic patient enrolment to glaucoma-related randomized controlled trials (RCTs) registered on ClinicalTrials.gov (to January 2023).Methods: Trials were included if they were at least double-masked, completed, and had published results through the registry or a scholarly journal. Sex-based glaucoma disease burden was identified using the Global Burden of Disease database. Pooled population-to-prevalence ratios (PPRs) with 95% confidence intervals (CI) were calculated for female sex, with values between 0.8 and 1.2 constituting sufficient study enrolment.Results: From 1061 records, we identified 177 trials (N = 38.475; 56.2% females) for inclusion in the study. The pooled female PPR was 1.05 [95% CI 1.02, 1.08]. Sub-group analysis revealed equitable female enrolment across study characteristics, although studies published prior to 1997 were indeterminate on whether they under-enrolled female participants.Conclusions: Overall, US-registered, glaucoma-related trials enrolled acceptable proportions of females based on real-world disease burden. Future trial enrolment should strive for equitable demographic representation.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"542-546"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144967686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lacrimal History - Part 63: Doyens of Dacryology Series - Jacob Parsons Schaeffer (1878-1970) and the Embryology of the Lacrimal Drainage System. 泪史-第63部分：泪学系列-雅各布·帕森斯·谢弗（1878-1970）和泪道引流系统的胚胎学。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2025-10-11 DOI: 10.1080/08820538.2025.2574190

Mohammad Javed Ali

引用次数: 0

Paradoxical Development of IgG4-Related Ophthalmic Disease During Dupilumab Therapy. 杜比单抗治疗期间igg4相关眼科疾病的矛盾发展

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2026-01-13 DOI: 10.1080/08820538.2026.2614750

Isana Nakajima, Ken Fukuda, Masato Okada, Kenji Yamashiro, Hideki Tsuji

引用次数: 0

Large Language Models Use in Dry Eye Disease: Correspondence. 大型语言模型在干眼病中的应用：对应。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2026-02-18 DOI: 10.1080/08820538.2026.2633400

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane - BRICS Report #1. 一项比较玻璃体内布卢珠单抗与安慰剂治疗慢性中枢性浆液性脉络膜视网膜病变的随机对照试验方案- BRICS报告#1

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2025-03-28 DOI: 10.1080/08820538.2025.2478072

Srishti Raksheeth Ramamurthy, Saarang Hansraj, Ritesh Narula, SriniVas R Sadda, Sobha Sivaprasad, Jay K Chhablani, Mudit Tyagi, Nikitha Gurram Reddy, Umesh Chandra Behera, Raja Narayanan

{"title":"Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane - BRICS Report #1.","authors":"Srishti Raksheeth Ramamurthy, Saarang Hansraj, Ritesh Narula, SriniVas R Sadda, Sobha Sivaprasad, Jay K Chhablani, Mudit Tyagi, Nikitha Gurram Reddy, Umesh Chandra Behera, Raja Narayanan","doi":"10.1080/08820538.2025.2478072","DOIUrl":"10.1080/08820538.2025.2478072","url":null,"abstract":"Purpose: Established consensus is lacking for the management of chronic central serous chorioretinopathy (CSCR). The role of anti-VEGF agents in treating chronic CSCR in the absence of choroidal neovascular membrane (CNVM) is equivocal. We aim to study intravitreal brolucizumab in the treatment of persistent macular fluid in chronic CSCR without CNVM.Methods: This study is a prospective randomized, placebo-controlled trial to be conducted among 42 patients with chronic CSCR (>3 months duration) with persistent intraretinal and/or subretinal fluid. Patients will be randomized in a 1:1 ratio to receive brolucizumab or oral multivitamins. Primary endpoint will be fluid resolution on OCT at 1 and 3 months. Secondary outcome measures will include the best-corrected visual acuity, microperimetry and NEI-VFQ 25 subjective questionnaire.Conclusion: The results of this study will provide an understanding of the efficacy and safety of brolucizumab in achieving fluid resolution in chronic CSCR without CNVM.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"508-514"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibrin Glue-Assisted Repair in Recurrent Retinal Detachment Following Post-Viral Retinitis: A Retrospective Analysis of 12 Cases in HIV-Positive Patients. 纤维蛋白胶辅助修复病毒性视网膜炎后复发性视网膜脱离：12例hiv阳性患者的回顾性分析。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2025-08-12 DOI: 10.1080/08820538.2025.2547322

Vikas Ambiya, Gaurav Kapoor, Mehak Aggarwal, Vijay K Sharma, Sunandan Bhatta

{"title":"Fibrin Glue-Assisted Repair in Recurrent Retinal Detachment Following Post-Viral Retinitis: A Retrospective Analysis of 12 Cases in HIV-Positive Patients.","authors":"Vikas Ambiya, Gaurav Kapoor, Mehak Aggarwal, Vijay K Sharma, Sunandan Bhatta","doi":"10.1080/08820538.2025.2547322","DOIUrl":"10.1080/08820538.2025.2547322","url":null,"abstract":"Purpose: To evaluate the anatomical and functional outcomes of fibrin glue application in the surgical management of recurrent rhegmatogenous retinal detachment (RRD) in patients with healed post-viral retinitis and HIV infection.Methods: A retrospective review was conducted of 40 cases of RRD secondary to viral retinitis in HIV-positive patients. Among these, 12 eyes exhibited recurrent detachment under silicone oil and were managed with silicone oil exchange, using fibrin glue to close persistent retinal breaks. Pre- and postoperative visual acuity, anatomical reattachment, and complications were assessed. The time to fibrin glue resorption and any evidence of epiretinal membrane formation were also recorded.Results: All 12 cases achieved successful retinal reattachment post fibrin glue application. Silicone oil removal was performed between 3 to 4 months postoperatively. Best corrected visual acuity improved in all eyes (mean preoperative LogMAR VA 1.2 ± 0.13 improved to 0.53 ± 0.13, p < .001). There were no pre-operative or post-operative complications. Nineteen of the total 40 cases required concurrent cataract surgery.Conclusion: Fibrin glue is a safe and effective adjunct for managing persistent retinal breaks in recurrent RRD under silicone oil in HIV-positive individuals with resolved viral retinitis. It promotes retinal reattachment and improves visual outcomes with minimal complications.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"532-536"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lacrimal History - Part 46: Doyens of Dacryology Series - James Ware (1756-1815) and His Three Lacrimal Treatises. 泪史-第46部分：泪学系列-詹姆斯·韦尔（1756-1815）和他的三篇泪学论文。

IF 2.3 4区医学

Seminars in Ophthalmology Pub Date : 2026-05-01 Epub Date: 2025-08-14 DOI: 10.1080/08820538.2025.2547159

Mohammad Javed Ali

引用次数: 0